ALLMedicine™ Multiple Myeloma Center
Research & Reviews 9,893 results
https://doi.org/10.1016/S2352-3026(22)00002-3
The Lancet. Haematology; Kapoor P, Gonsalves WI
Jan 16th, 2022 - Melflufen for multiple myeloma: a promise unfulfilled?|2022|Kapoor P,Gonsalves WI,|
https://doi.org/10.1016/S2352-3026(21)00381-1
The Lancet. Haematology; Schjesvold FH, Dimopoulos MA et. al.
Jan 16th, 2022 - Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provide a pro...
https://doi.org/10.1016/j.clml.2021.12.017
Clinical Lymphoma, Myeloma & Leukemia; Rubens M, Cristian A et. al.
Jan 15th, 2022 - Frailty could affect outcomes of autologous hematopoietic stem cell transplantation (aHSCT). This study sought to examine the effects of frailty on hospital outcomes among patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and multip...
https://doi.org/10.1007/s00330-021-08311-z 10.1259/bjr.20180768 10.1016/S1470-2045(09)70190-1 10.1016/S1470-2045(16)30206-6 10.1111/bjh.14827 10.1148/radiol.2019181949 10.1016/j.crad.2016.07.007 10.1111/j.1365-2141.2011.08658.x 10.1007/s13244-016-0492-7 10.1016/j.acra.2010.08.002 10.1259/bjr/52759767 10.1148/radiol.13131529 10.1016/j.acra.2015.05.011 10.1007/s00330-017-4907-8 10.1016/j.crad.2017.05.004 10.1016/j.acra.2017.12.008 10.1016/j.ejrad.2019.108695 10.1371/journal.pone.0229607 10.1186/s40644-020-0293-6 10.7326/0003-4819-155-8-201110180-00009 10.1177/0004563217710489 10.3324/haematol.2018.189159 10.1136/bmj.327.7414.557 10.1136/bmj.315.7109.629 10.1016/j.jclinepi.2007.11.010 10.1016/j.eururo.2016.05.033 10.1007/s00330-011-2116-4 10.1007/s00330-009-1469-4 10.1002/ijc.28877 10.1148/radiol.2016160363 10.1182/bloodadvances.2016000117 10.1038/s41375-018-0329-0 10.3390/jcm9113519 10.1056/NEJMoa1506348 10.1056/NEJMoa1817226 10.1016/S2352-3026(19)30115-2 10.1038/s41571-020-0427-6
European Radiology; Wang K, Lee E et. al.
Jan 15th, 2022 - Myeloma Response Assessment and Diagnosis System recently published provides a framework for the standardised interpretation of DW-WBMRI in response assessment of multiple myeloma (MM) based on expert opinion. However, there is a lack of meta-anal...
https://doi.org/10.1038/s41375-021-01492-y
Leukemia Waldschmidt JM, Yee AJ et. al.
Jan 15th, 2022 - Interrogation of cell-free DNA (cfDNA) represents an emerging approach to non-invasively estimate disease burden in multiple myeloma (MM). Here, we examined low-pass whole genome sequencing (LPWGS) of cfDNA for its predictive value in relapsed/ re...
Guidelines 34 results
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.
Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.
Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,
https://doi.org/10.6004/jnccn.2020.0057
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.
Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.
Dec 6th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.
Sep 26th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...
Drugs 143 results see all →
Clinicaltrials.gov 815 results
https://clinicaltrials.gov/ct2/show/NCT03758417
Jan 14th, 2022 - The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.
https://clinicaltrials.gov/ct2/show/NCT03170882
Jan 14th, 2022 - The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have relapsed and/or refractory multiple myeloma (RRMM). This study will compare the efficacy and safety in participants who take ixazomib and dex...
https://clinicaltrials.gov/ct2/show/NCT05020236
Jan 14th, 2022 - The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a ...
https://clinicaltrials.gov/ct2/show/NCT02465060
Jan 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...
https://clinicaltrials.gov/ct2/show/NCT04933539
Jan 14th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...
News 1,786 results
https://www.onclive.com/view/selecting-the-optimal-treatment-approach-for-difficult-to-treat-relapsed-refractory-myeloma
Jan 14th, 2022 - Certain patient and disease characteristics must be considered to select the optimal treatment approach for difficult-to-treat patients with relapsed or refractory multiple myeloma, according to Alessandra Larocca, MD, PhD, who added that the intr...
https://www.medscape.com/viewarticle/842817
Jan 14th, 2022 - Multiple myeloma is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Because the antibody-forming cells (ie, plasma cells) are malignant, th...
https://reference.medscape.com/viewarticle/949631
Jan 11th, 2022 - Multiple myeloma is a hematologic cancer in which monoclonal plasma cells proliferate in the bone marrow, destroying bone and displacing other hematopoietic cell lines. Its presentation can range from asymptomatic to severely symptomatic, with com...
https://www.medscape.com/viewarticle/949631
Jan 11th, 2022 - Multiple myeloma is a hematologic cancer in which monoclonal plasma cells proliferate in the bone marrow, destroying bone and displacing other hematopoietic cell lines. Its presentation can range from asymptomatic to severely symptomatic, with com...
https://www.medscape.com/viewarticle/962961
Jan 11th, 2022 - Multiple myeloma is a plasma cell cancer characterized by proliferation of monoclonal plasma cells in bone marrow, leading to an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell...
